Skip to main content
Journal for Immunotherapy of Cancer logoLink to Journal for Immunotherapy of Cancer
. 2021 Oct 6;9(10):e003149corr1. doi: 10.1136/jitc-2021-003149corr1

Correction: Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design

PMCID: PMC8496374  PMID: 34615707

Qin H, Yang L, Chukinas JA, et al. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design. J ImmunoTher Cancer 2021;9:e003149. doi: 10.1136/jitc-2021-003149

This article has been corrected since it was first published. Middle initials have been added to author names ‘Nirali N Shah’ and ‘Naomi A Taylor’.


Articles from Journal for Immunotherapy of Cancer are provided here courtesy of BMJ Publishing Group

RESOURCES